Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463068 · ClinicalTrials.gov registry record · Phase 3
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
A Phase 3 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 3
- Development phase
- 911
- Enrollment target
NCT05463068: Completed Phase 3 study, sponsored by Novavax.
NCT05463068 is a Phase 3 study that has completed, run by Novavax. The registered enrollment target is 911 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463068, a Phase 3 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 911 participants
- Enrollment target
Study Summary
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
Primary Outcome
Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.
Interventions
- DRUG NVX-Cov2373
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 3 |
What the finished NCT05463068 record still lists
NCT05463068 is an interventional study that assigns participants to a tested intervention. The registered 911 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 1 intervention - of which NVX-Cov2373 is the first listed.
NCT05463068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05463068 about?
NCT05463068 is a clinical study titled "Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults". This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
What is the current status of trial NCT05463068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2022-07-11. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT05463068?
The interventions under investigation include: NVX-Cov2373 (DRUG).
Who is sponsoring clinical trial NCT05463068?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05463068's enrollment target sits among peer trials
911 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI